AVTX (Avalo Therapeutics) FFO


AVTX Avalo Therapeutics Inc AVTX
23 GF Score
Price $18.20
GF Value $0.03
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Avalo Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

AVTX
23GF Score
Avalo Therapeutics Inc AVTX
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Avalo Therapeutics (AVTX) Overvalued in 2026?

Based on GuruFocus' analysis, Avalo Therapeutics stock appears to be overvalued. The current stock price of $18.20 is trading 60566.7% above its estimated GF Value™ of $0.03. GuruFocus considers Avalo Therapeutics to be Significantly Overvalued.

Key valuation signals for AVTX:

  • FFO:
  • GF Value™: $0.03 vs. price of $18.20 (60566.7% above fair value)
  • GF Score™: 23/100 with 5 warning signs

No single metric tells the full story. See the AVTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Avalo Therapeutics Business Description

Other Exchanges C6K0:Germany
Address 1500 Liberty Ridge Drive, Suite 321, Wayne, PA, USA, 19087
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
23GF Score

Get the complete analysis for AVTX

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.20
Price
$0.03
GF Value